Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults.
Treatment with carbamazepine (CBZ) affects cholesterol concentrations, but little is known about the precise nature and underlying mechanisms of changes in lipoprotein metabolism. We investigated prospectively the effects of CBZ on lipid metabolism in normolipemic adults. In 21 healthy males, lipoprotein and noncholesterol sterol concentrations were measured before and during treatment with CBZ for 70 +/- 18 days. Thirteen subjects underwent kinetic studies of apolipoprotein-B (ApoB) metabolism with the use of endogenous stable isotope labeling. Lipoprotein kinetic parameters were calculated by multicompartmental modeling. Significant increases in total cholesterol, in ApoB-containing lipoproteins [very-low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low-density lipoprotein (LDL)], and in triglycerides, but not in high-density lipoprotein (HDL), were observed. Lipoprotein particle composition remained unchanged. Mean fractional catabolic and production rates of ApoB-containing lipoproteins were not significantly different, although mean production rates of VLDL and IDL were substantially increased (+46 +/- 139% and +30 +/- 97%, respectively), whereas mean production of LDL remained unchanged (+2.1 +/- 45.6%). Cholestanol in serum increased significantly but not the concentrations of plant sterols (campesterol, sitosterol) and the cholesterol precursors (lathosterol, mevalonic acid). There was a significant correlation between the decrease in free thyroxine and the increase in IDL cholesterol. Treatment with CBZ increases mainly ApoB-containing lipoproteins. CBZ seems not to influence endogenous cholesterol synthesis or intestinal absorption directly. The increase is neither related to increased ApoB production nor to decreased catabolism but is rather due to changes in the conversion cascade of IDL particles, most likely as an indirect effect through a decrease in thyroid hormones.
Brämswig
Susanne
S
Department of Clinical Pharmacology, University of Bonn, 53105 Bonn, Germany.
Kerksiek
Anja
A
Sudhop
Thomas
T
Luers
Claus
C
Von Bergmann
Klaus
K
Berthold
Heiner K
HK
D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D001161:Arteriosclerosis / Q000097:blood; D001823:Body Composition; D001835:Body Weight; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects*; D004083:Cholestanol / Q000097:blood / Q000493:pharmacokinetics; D002784:Cholesterol / Q000031:analogs & derivatives* / Q000097:blood; D008076:Cholesterol, HDL / Q000096:biosynthesis / Q000097:blood; D008078:Cholesterol, LDL / Q000096:biosynthesis / Q000097:blood; D015243:Cholesterol, VLDL / Q000096:biosynthesis / Q000097:blood; D004032:Diet; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives* / Q000097:blood; D007408:Intestinal Absorption; D008074:Lipoproteins / Q000096:biosynthesis / Q000097:blood*; D008297:Male; D008798:Mevalonic Acid / Q000097:blood / Q000652:urine; D010840:Phytosterols / Q000097:blood / Q000493:pharmacokinetics; D012855:Sitosterols / Q000097:blood
D000927:Anticonvulsants; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D008074:Lipoproteins; D010840:Phytosterols; D012855:Sitosterols; D002220:Carbamazepine; C001380:6 beta-hydroxycortisol; C021273:campesterol; C025473:gamma-sitosterol; C001521:lathosterol; D004083:Cholestanol; D002784:Cholesterol; D008798:Mevalonic Acid; D006854:Hydrocortisone